Data gathered: April 15
AI Stock Analysis - TG Therapeutics (TGTX)
Analysis generated March 27, 2025. Powered by Chat GPT.
TG Therapeutics, Inc. (TGTX) is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases. Its current portfolio includes Ublituximab, a monoclonal antibody, and Umbralisib, an oral inhibitor of PI3K delta. The company capitalizes on innovative therapies to target unmet medical needs, especially in contexts such as oncology and autoimmune diseases. Given its research focus and niche operations, TG Therapeutics is positioned to potentially make significant advancements in medical treatments, though it also faces considerable investment risks due to the volatile nature of the biopharmaceutical sector.
Stock Alerts - TG Therapeutics (TGTX)
 |
TG Therapeutics | April 9 Price is down by -5.7% in the last 24h. |
|
TG Therapeutics | April 8 Price is down by -5.2% in the last 24h. |
|
TG Therapeutics | April 7 Price is down by -7.3% in the last 24h. |
|
TG Therapeutics | April 4 Price is down by -6.2% in the last 24h. |
Alternative Data for TG Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 3 | Sign up | Sign up | Sign up |
| Sentiment | 97 | Sign up | Sign up | Sign up |
| Webpage traffic | 9,000 | Sign up | Sign up | Sign up |
| Employee Rating | 46 | Sign up | Sign up | Sign up |
| Google Trends | 48 | Sign up | Sign up | Sign up |
| Patents | 7 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 526 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 20,517 | Sign up | Sign up | Sign up |
| Twitter Followers | 3,129 | Sign up | Sign up | Sign up |
| Twitter Mentions | 34 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 20 | Sign up | Sign up | Sign up |
| Linkedin Employees | 409 | Sign up | Sign up | Sign up |
About TG Therapeutics
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases.
| Price | $38.41 |
| Target Price | Sign up |
| Volume | 4,570,000 |
| Market Cap | $5.77B |
| Year Range | $19.92 - $42.99 |
| Dividend Yield | 0% |
| PE Ratio | 244.73 |
| Analyst Rating | 83% buy |
| Industry | Biotechnology |
In the news
 |
TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Franklin Resources Inc.April 13 - ETF Daily News |
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual MeetingApril 10 - GlobeNewswire |
|
 |
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's WhyApril 10 - Yahoo |
|
Sei Investments Co. Decreases Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)April 9 - ETF Daily News |
 |
TG Therapeutics announces data presentations for BRIUMVI at AAN 2025 MeetingApril 8 - Thefly.com |
|
Norges Bank Makes New $12.09 Million Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)April 8 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 84M | 51M | 33M | 3.9M | 15M | 0.020 |
| Q2 '24 | 73M | 47M | 26M | 6.9M | 11M | 0.040 |
| Q1 '24 | 63M | 40M | 23M | -11M | -8.3M | -0.070 |
| Q4 '23 | 42M | 39M | 2.7M | -14M | -12M | -0.100 |
| Q3 '23 | 162M | 36M | 126M | 114M | 115M | 0.730 |
Insider Transactions View All
| Power Sean A filed to sell 660,611 shares at $28.5. January 7 '25 |
| Power Sean A filed to sell 670,632 shares at $30.3. January 7 '25 |
| Lonial Sagar filed to sell 100,195 shares at $30.4. November 12 '24 |
| Charney Laurence N filed to sell 212,479 shares at $30.2. November 12 '24 |
| Echelard Yann filed to sell 224,098 shares at $24.5. November 7 '24 |
Similar companies
Read more about TG Therapeutics (TGTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of TG Therapeutics?
The Market Cap of TG Therapeutics is $5.77B.
What is TG Therapeutics' PE Ratio?
As of today, TG Therapeutics' PE (Price to Earnings) ratio is 244.73.
What is the current stock price of TG Therapeutics?
Currently, the price of one share of TG Therapeutics stock is $38.41.
How can I analyze the TGTX stock price chart for investment decisions?
The TGTX stock price chart above provides a comprehensive visual representation of TG Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling TG Therapeutics shares. Our platform offers an up-to-date TGTX stock price chart, along with technical data analysis and alternative data insights.
Does TGTX offer dividends to its shareholders?
As of our latest update, TG Therapeutics (TGTX) does not offer dividends to its shareholders. Investors interested in TG Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of TG Therapeutics?
Some of the similar stocks of TG Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.